HLA-A*0301 & B2M & KRASG12C (VVGACGVGK)

HLA-A*0301 & B2M & KRASG12C (VVGACGVGK)

HLA-A*0301 & B2M & KRASG12C (VVGACGVGK) Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
ACC-006ACC-006Phase 2 ClinicalJiangsu Aidea Pharmaceutical Co Ltd, China Pharmaceutical University
Solid tumours; Carcinoma, Non-Small-Cell Lung
Details
SulforadexSFX-01Phase 2 ClinicalEvgen Pharma, Lalilab, Pharmagra Labs Inc
Autistic Disorder; Thrombosis; Precancerous Conditions; Ventricular Dysfunction, Left; Subarachnoid Hemorrhage; Lung Neoplasms; Renal Insufficiency, Chronic; Parkinson Disease; Asthma; Hyperplasia; Prostatic Neoplasms; Carcinoma in Situ; Breast Neoplasms; Head and Neck Neoplasms; Small Cell Lung Carcinoma; Kidney Diseases; Heart Diseases; Neoplasms; Neurodevelopmental Disorders; Nasolabial fold wrinkles; Schizophrenia; Anaplasia; Squamous Cell Carcinoma of Head and Neck; Autism Spectrum Disorder; Drug-Related Side Effects and Adverse Reactions; Heart Failure, Diastolic
Details
NLM-001NLM-001Phase 2 ClinicalNelum Corp
Carcinoma, Pancreatic Ductal
Details
IMP5471-CAPhase 1 ClinicalShanghai Impact Pharmaceutical Co Ltd
Hematologic Diseases
Details